Healthcare Holding B.V. Gilde Sells 10,751 Shares of Shoulder Innovations (NYSE:SI) Stock

Shoulder Innovations, Inc. (NYSE:SI) major shareholder Healthcare Holding B.V. Gilde sold 10,751 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $22.71, for a total transaction of $244,155.21. Following the sale, the insider owned 2,321,452 shares in the company, valued at approximately $52,720,174.92. This trade represents a 0.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Healthcare Holding B.V. Gilde also recently made the following trade(s):

• On Tuesday, August 4th, Healthcare Holding B.V. Gilde sold 99,812 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.77, for a total transaction of $2,272,719.24.
• On Friday, July 31st, Healthcare Holding B.V. Gilde sold 20,034 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.73, for a total transaction of $455,372.82.
• On Thursday, July 30th, Healthcare Holding B.V. Gilde sold 28,245 shares of Shoulder Innovations stock. The stock was sold at an average price of $23.36, for a total transaction of $659,803.20.

Shoulder Innovations Price Performance

Shares of NYSE SI opened at $22.36 on Friday. The company has a 50 day simple moving average of $19.79 and a two-hundred day simple moving average of $16.04. Shoulder Innovations, Inc. has a fifty-two week low of $10.92 and a fifty-two week high of $24.59. The company has a market capitalization of $463.85 million and a price-to-earnings ratio of -0.13. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.04 and a current ratio of 11.81.

Shoulder Innovations (NYSE:SI) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.03. The firm had revenue of $16.71 million for the quarter. Shoulder Innovations had a negative return on equity of 35.11% and a negative net margin of 81.78%. Analysts expect that Shoulder Innovations, Inc. will post -1.67 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on SI shares. Piper Sandler restated an “overweight” rating and set a $19.00 price target (up from $18.00) on shares of Shoulder Innovations in a report on Friday, May 8th. UBS Group assumed coverage on shares of Shoulder Innovations in a research note on Tuesday, July 28th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, Weiss Ratings raised shares of Shoulder Innovations from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Shoulder Innovations has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Key Headlines Impacting Shoulder Innovations

Here are the key news stories impacting Shoulder Innovations this week:

• Positive Sentiment: Second-quarter revenue rose 56% year over year to $17.18 million, slightly exceeding the $17.1 million consensus estimate. Gross profit increased 60% to $13.4 million, indicating continued demand and improving product economics. Q2 2026 earnings report
• Positive Sentiment: Management raised its full-year 2026 revenue outlook to $67 million-$69 million, broadly in line with the approximately $67.1 million analyst consensus. First-half revenue growth reached 60%, supporting the company’s expansion narrative. Company earnings release
• Positive Sentiment: Institutional interest was favorable overall: 43 investors increased positions in the latest quarter, compared with 13 that reduced holdings. BlackRock, Millennium Management and other firms reported sizable additions.
• Neutral Sentiment: Analyst sentiment remains generally constructive. UBS initiated coverage with a Buy rating and a $27 price target, while the broader consensus is Moderate Buy; however, reported target prices range from $19 to $27, reflecting valuation uncertainty.
• Negative Sentiment: Adjusted diluted EPS was negative $0.49, missing the roughly negative $0.46-$0.47 consensus. The company posted a $10.2 million net loss, an $10.0 million operating loss and used $7.4 million in operating cash, underscoring its ongoing path to profitability and funding risks.
• Negative Sentiment: Major shareholder Gilde Healthcare sold more than 150,000 shares across recent transactions, including approximately $2.3 million of sales on August 4. Although Gilde retains a substantial position, the repeated selling may weigh on investor sentiment. Gilde Healthcare insider sale

Institutional Trading of Shoulder Innovations

Several institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN grew its stake in Shoulder Innovations by 66.3% in the fourth quarter. Wells Fargo & Company MN now owns 5,250 shares of the company’s stock worth $75,000 after purchasing an additional 2,094 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Shoulder Innovations during the 3rd quarter valued at $28,000. Rhumbline Advisers purchased a new stake in shares of Shoulder Innovations in the 3rd quarter worth $54,000. Bank of America Corp DE lifted its holdings in shares of Shoulder Innovations by 43.7% in the 1st quarter. Bank of America Corp DE now owns 26,983 shares of the company’s stock worth $392,000 after buying an additional 8,205 shares during the period. Finally, Renaissance Technologies LLC bought a new position in shares of Shoulder Innovations during the 4th quarter worth $176,000.

About Shoulder Innovations

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.